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Summary
Patients with pneumocystis pneumonia have a risk of 
progressing to acute respiratory failure necessitating 
admission to intensive care. The case described is of a 
patient with a newly diagnosed HIV infection presenting 
with pneumocystis pneumonia. Despite initiating the 
appropriate pharmacological treatment the patient’s 
clinical condition deteriorated, and required both rescue 
pharmacological therapy with echinocandins as well 
as respiratory support with extracorporeal membrane 
oxygenation therapy. The patient recovered well on 
ventilator and circulatory support despite a long 
weaning process complicated by sequelae common to 
pneumocystis pneumonia. Following initialisation of 
antiretroviral therapy and step-down from an intensive 
care setting, the patient required further prolonged 
hospital stay for rehabilitation and mental health support 
before being discharged. This case reviews the novel 
pharmacological therapies and respiratory support 
strategies used in cases of pneumocystis pneumonia, 
including the clinical and psychological sequelae that 
may follow.
Background
Pneumonia due to Pneumocystis jirovecii (formerly 
carinii) is a subacute to acute pulmonary infection 
which develops in those who are immunosup-
pressed or profoundly malnourished, and is often 
fatal.1 Conventional therapeutic strategies against 
P. jirovecii revolve around early identification 
and severity scoring informing pharmacological 
therapy.2 Adjuvant therapy with corticosteroids has 
been found to contribute to significant reductions 
in mortality and need for mechanical ventilation, in 
particular pneumocystis pneumonia (PCP) and HIV 
coinfection.3 4 There are additional novel therapies 
that are known to be active against P. jirovecii, but 
these have not been subject to rigorous assessment 
in clinical trials, including treatment with new anti-
fungal agents such as the echinocandin class.5
In spite of increased access to antiretroviral 
therapy (ART), PCP secondary to HIV infection 
still occurs. PCP is also increasingly recognised as 
a complication of immunosuppression secondary 
to transplantation or chemotherapy. Cases of PCP 
that develop acute respiratory failure requiring 
intensive treatment unit (ITU) admission have a 
poor prognosis.6 Several studies have looked at 
modifying optimal mechanical ventilation strategies 
to improve outcomes in patients admitted to ITUs 
with PCP.6 7 Extracorporeal membrane oxygen-
ation (ECMO) supports gas exchange by pumping 
venous blood through an artificial membrane lung 
and returning it either into the venous (respiratory 
support) or arterial (cardiac support) systems.8 
Respiratory ECMO has been shown to improve 
disability-free survival,9 and is indicated for use in 
cases of acute respiratory distress syndrome (ARDS) 
with potentially reversible causes such as infec-
tious precipitants.10 11 Its benefit in cases of PCP 
requiring lung-protective ventilation has not been 
explored, and few cases have been reported in the 
literature.12–15
We present a case of a newly diagnosed patient 
infected with HIV who developed PCP that 
required ITU admission. This is an educational case 
because the patient did not respond to maximal 
conventional therapy and required both ECMO 
and the administration of an echinocandin rescue 
therapy. Few case reports exist for either thera-
pies in HIV-related PCP, and this report hopes to 
contribute to the growing body of literature.
caSe preSentation
This 54-year-old woman presented to a large 
teaching hospital with a 2-week history of fevers, 
difficulty in breathing and a non-productive cough. 
This was preceded by a 3-week history of malaise, 
nausea, and sharp chest and back pains. There was 
no history of palpitations or radiation of chest pain. 
She described a 9-month history of unintentional 
weight loss of 3–4 kg, with an accompanying loss in 
appetite and odynophagia.
Two weeks prior to presentation, she had seen 
her general practitioner who had empirically diag-
nosed a lower urinary tract infection and prescribed 
a week-long course of trimethoprim, followed by 
another week’s course of amoxicillin/clavulanic 
acid. She did not improve following these treat-
ments, and called ambulance services when she 
developed clinical anorexia, vomiting, fevers and 
difficulty in breathing. Her significant prior medical 
history included a depressive disorder, hyperten-
sion, hypercholesterolaemia, gastric acid-reflux 
disease and eczema. She owned a private business, 
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but was not able to work for several months due to poor health. 
She lived with her adolescent son, and was independent in all 
activities of daily living. She was an ex-smoker with a 7 pack-
year history. She described a recent alcohol intake history of an 
estimated 60 units per week for at least a few months. She did 
not take any illicit substances, injected or otherwise, and did 
not report any recent sexual contacts in the last 5 years. She 
described having been sexually assaulted 20 years ago, but pene-
trative intercourse did not occur. She did not report a history of 
having been investigated for sexually transmitted infections, but 
her last HIV test was 5 years prior and was negative. Her long-
term medication included fluoxetine and lisinopril. She was not 
known to be allergic to any medications.
On general inspection, she appeared fatigued. She had a 
temperature of 36.4°C. She had a respiratory rate of 20 breaths 
per minute, with a capillary oxygen saturation reading of 95% 
on room air. Her heart rate was 78 beats per minute, with a 
non-invasive blood pressure of 155/85 mm Hg. Her Glasgow 
Comma Scale score was 15/15. Examination of her chest was 
completely unremarkable, and examination of the other major 
systems did not yield any contributory information.
A working diagnosis of a community-acquired pneumonia 
was established, and the patient was admitted for further inves-
tigations and management. Her initial investigations are given 
below. Her initial CURB-65 severity score was calculated as 
zero. Further investigations were conducted to look for atypical 
infecting organisms, including HIV testing. She was managed 
with appropriate fluid resuscitation and intravenous amoxicillin 
and clarithromycin for broad spectrum and appropriate atypical 
organism coverage.
On day 1 of the pre-ECMO admission period, the patient 
became markedly hypoxic. An arterial blood gas performed 
with 2 L of O2 being delivered through nasal cannulae yielded 
a pH 7.49, pO2 7.1 kPa, pCO2 4.0 kPa, BE 0 mmol/L and an 
HCO3 22.9 mmol/L. A CT pulmonary angiogram performed 
on the same day ruled out a pulmonary embolus as a cause of 
hypoxia, but confirmed a diffuse pneumonitis.
On day 2 pre-ECMO, the patient’s HIV test was reported 
as positive using two separate fourth-generation test kits. The 
clinical picture of hypoxia, cough and consolidative changes in 
the lung in the context of a new HIV diagnosis with a history of 
weight loss signifying chronicity of disease suggested a unifying 
diagnosis of P. jirovecii pneumonia. Oral hair leukoplakia and 
oral candidiasis were clinically identified on further inspec-
tion. Previous antibiotics were stopped and intravenous pipera-
cillin/tazobactam was commenced due to evidence of clinical 
deterioration. Cotrimoxazole, prednisolone and fluconazole 
were started as treatment for presumed pneumocystis and oral 
candidiasis.
On day 3 pre-ECMO, CD4 quantification revealed 12 cells/
mm3 consistent with an advanced, late presentation of HIV. She 
developed a normocytic anaemia with a serum lactate dehydro-
genase (LDH) of 1431 units/L. The patient was transferred to an 
intensive care setting due to deteriorating ventilation resulting 
in type 1 respiratory failure requiring non-invasive ventilation 
oxygen delivery strategies. Despite being managed on non-in-
vasive continuous positive airway pressure ventilation (set at 
positive end-expiratory pressure (PEEP) 10 and FiO2 65%), her 
capillary oxygen saturations remained between 88% and 90%.
On day 5 pre-ECMO, deteriorating oxygen requirements 
necessitated elective endotracheal intubation and mechanical 
ventilation. In accordance with evidence-based recommenda-
tions, a lung-protective ventilation strategy was employed; with 
tidal volumes aimed at 6 mL/kg and peak inspiratory pressures 
<30 mm Hg.16 Bronchoalveolar washout was performed, and an 
immunofluorescence test confirmed the presence of P. jirovecii.
By day 10 pre-ECMO, she had progressively worsening hyper-
capnia and borderline metabolic acidosis. Her serum lactate 
LDH continued to be raised (1349 units/L). It is recognised 
that P. jirovecii infection causes an increase in LDH, but on the 
basis of possible ineffective treatment and a worsening anaemia 
signalling potential haemolysis after 5 days of cotrimoxazole, 
second-line P. jirovecii treatment was initiated with clindamycin 
and primaquine. A referral to the national ECMO service was 
made. The patient was placed in the prone position in an attempt 
to improve gas exchange.17 Her ECG showed a new left bundle 
branch block, but a bedside transthoracic echocardiogram (TTE) 
showed good biventricular function. Due to the clinical deteri-
oration, rescue therapy using caspofungin for P. jirovecii infec-
tion was initiated. Despite these measures, the patient became 
increasingly haemodynamically unstable and required increasing 
therapeutic oxygen requirements. A decision was made to place 
her on respiratory ECMO via bifemoral venous cannulation (23 
and 25 FR), and she was retrieved to one of the five UK national 
commissioned ECMO centres for further management.
inveStigationS
The day 0 pre-ECMO admission investigations are as follows. 
The hospital initial laboratory tests were: haemoglobin 11.6 g/L, 
total white blood cell count 8.0×109 cells/L, neutrophils 6.4 (109 
cells/L), lymphocytes 3.66 (109 cells/L), platelets 349×109 cells/L, 
bilirubin 5 μmol/L, albumin 34 g/L, globulin 41 g/L, alkaline 
phosphatase 181 IU/L, alanine transaminase 34 IU/L, sodium 
131 mmol/L, potassium 4.1 mmol/L, blood urea nitrogen 3.2 mg/
dL, creatinine 48 μmol/L and an estimated glomerular filtration 
rate >60. The admission chest radiograph is shown in figure 1. 
The admission CT pulmonary angiography is shown in figures 2 
and 3.
The subsequent pre-ECMO and peri-ECMO admission period 
investigations are as follows. Initial viral screens and quantifica-
tions yielded a CD4 count of 12 cells/mm3 and an HIV viral load 
count of 1 075 702 copies/mL. Immunoassay or PCR screening 
Figure 1 Admission chest radiograph (posteroanterior).
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for viral hepatitides, syphilis, cryptococcal antigen, toxoplasma 
and human herpesvirus-8 was unremarkable. Cytomegalovirus 
(CMV) DNA PCR reported 382 copies/mL. Initial beta-D-
glucan antigen assays reported concentration of >523 pg/mL. 
Subsequent PCR from bronchoalveolar lavage samples reported 
P. jirovecii DNA as detected. HIV resistance investigations 
reported a wild-type infection fully susceptible to all ART. Peri-
admission (day 15) viral screens yielded a CMV DNA PCR result 
of 54 600 copies/mL.
treatment
On admission to the regional ECMO centre’s ITU, the patient 
was placed on an ultraprotective ventilation strategy, aiming for 
tidal volumes of 3 mL/kg. She remained cardiovascularly unsup-
ported and haemodynamically stable. A repeat bedside TTE 
showed preserved biventricular function. Her ECMO flow rate 
was set at 3 L/min with a sweep gas flow rate set at 1.5 L/min. 
A high-resolution CT employing low and high levels of PEEP 
to assess recruitability showed worsening consolidative and 
ground-glass changes throughout the lung (figures 4 and 5). 
Second-line and rescue treatments for PCP were continued, and 
intravenous methylprednisolone was added.
Figure 2 Admission CT pulmonary angiography (level of bifurcation 
of carina).
Figure 3 Admission CT pulmonary angiography (base of lungs).
Figure 4 Post-ECMO (extracorporeal membrane 
oxygenation) cannulation high-resolution CT with positive end-
expiratory pressure (level of bifurcation of carina).
Figure 5 Post-ECMO (extracorporeal membrane 
oxygenation) cannulation high-resolution CT with positive end-
expiratory pressure (bases of lungs).
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Improvement in clinical status and evidence of only single-
organ failure allowed for early extubation onto high flow nasal 
cannulae on day 1 post-ECMO cannulation. The patient toler-
ated this well, and ECMO settings remained with a flow rate of 
3 L/min with a sweep gas flow rate of 3.5 L/min. By ECMO day 
3, the patient’s clinical condition had dramatically improved, 
and she began working with physiotherapy teams to complete 
bedside exercises with no significant compromise to her ECMO 
circuit flow. Due to her improving clinical condition, she began 
to be weaned off the ECMO circuit, made difficult by triggers 
of dyspnoea and anxiety. On ECMO day 8, to address ongoing 
ECMO weaning difficulties, she was assessed by clinical psychol-
ogist who recommended anxiolytics when it was determined 
that she had developed feelings of anxiety triggered by memories 
or thoughts of her critical illness.
On ECMO day 12, ART therapy was started. Her initial 
therapy included tenofovir alafenamide and emtricitabine 
(Descovy), and darunavir/cobivstat (Rezolsta) combination 
therapy. On ECMO day 15, routine investigations revealed an 
increasing CMV viral load for which she started on intrave-
nous ganciclovir. On ECMO day 16, her fluoxetine dose was 
increased to address an ongoing adjustment disorder following 
her HIV diagnosis and intensive care admission on a back-
ground of an existing mood disorder. This resulted in a posi-
tive effect on her mood and engagement with rehabilitation 
activities.
On ECMO day 19, she was given a trial of a reduced sweep 
gas flow rate, resulting in a drop of peripheral oxygen satura-
tions to 85% accompanied by an increased work of breathing 
despite supplemental oxygen therapy. A repeat high-resolution 
CT chest scan confirmed increased fibrotic and bronchiectatic 
changes throughout the lung, with new bilateral small pneumo-
thoraces which were not compromising her oxygenation. She was 
given pulsed intravenous methylprednisolone doses for 3 days, 
followed by a tapering high-dose hydrocortisone maintenance 
therapy. On ECMO day 24, she was again trialled off sweep gas 
flow rate and managed to maintain good gas exchanges on nasal 
high-flow oxygen delivery. On ECMO day 28, sweep gas flow 
rates were reduced to zero, and on ECMO day 31 her ECMO 
cannulae were removed. This resulted in an improvement in her 
mood disorder as she began to work more intensively with reha-
bilitation teams.
outcome and Follow-up
Post-ECMO decannulation, discharge planning for repatria-
tion back to the referring hospital was initiated. However, by 
post-ECMO day 5, it was noted on routine X-ray imaging that 
her right pneumothorax had increased in size despite engaging 
well with rehabilitation. A repeat CT scan showed an enlarging 
pneumothorax, and subsequently a CT-guided chest drain 
was inserted (figures 6–8). Subsequent repeat X-ray imaging 
postdrain insertion showed good lung re-expansion.
Post-ECMO day 9, the patient was transferred back to the 
referring hospital with continuing ART, clindamycin and 
primaquine for PCP, gancyclovir for CMV viraemia, azithro-
mycin for Mycobacterium avium complex prophylaxis and 
fluconazole for Cryptococcus spp. prophylaxis. She was stepped 
down to prophylactic cotrimoxazole and, as her CMV DNA was 
undetectable, she switched from gancyclovir to oral valgancy-
clovir. Repeat HIV viral parameters confirmed a CD4 count of 
50 cells/mm3 and a viral load of 1555 copies/mL. The right-sided 
pneumothorax had resolved and the chest drain was removed 
3 days after arrival to the referring hospital; however, she 
continued to have a persistent small left-sided pneumothorax 
which did not cause any clinical compromise.
The patient remained stable for 1 week before developing a 
recurrence of the right-sided pneumothorax. A chest drain was 
reinserted with minimal effect, and a decision was made after 
discussion with the patient to not insert further chest drains 
unless she developed respiratory compromise.
The patient’s prolonged period of recovery was complicated 
by significant weight loss and poor oral intake prompted by her 
deteriorating mental health. A psychiatric assessment concluded 
that the patient was suffering from a depressive episode in the 
context of an adjustment reaction to her current illness on the 
background of an undiagnosed personality disorder. Consequen-
tial difficulties in her ongoing management prompted detention 
under the UK’s Mental Health Act (MHA) for diagnosis and 
treatment of her underlying mental health disorder. Under these 
Figure 6 Postchest drain insertion high-resolution CT (lung apices).
Figure 7 Postchest drain insertion high-resolution CT (level of 
bifurcation of carina).
 o
n
 4 January 2019 by guest. Protected by copyright.
http://casereports.bmj.com/
BM
J Case Reports: first published as 10.1136/bcr-2017-221214 on 4 O
ctober 2017. Downloaded from
 
5Lee N, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2017-221214
novel treatment (new drug/intervention; established drug/procedure in new situation)
conditions, she was managed with neuroleptic medication as well 
as receiving nasogastric feeding for 5 weeks. As her mental state 
improved, the detention order under the MHA was rescinded 
and a complex discharge process back to her own home was 
arranged.
Three months post-ECMO, repeat viral parameters yielded 
a CD4 count of 50 cells/mm3 and a viral load of 684 copies/
mL. Prior to discharge advance care decisions were made 
during which the patient stated a wish to not be for cardio-
pulmonary resuscitation, to not be transferred to an intensive 
care unit and to not have any further chest drains inserted. 
On prompting the patient for further thoughts and reflections 
on recent events, during numerous occasions she had stated 
that she would not have consented to intubation or ECMO 
had she known how traumatic these interventions would have 
been. The patient was discharged back home at 4 months 
post-ECMO.
diScuSSion
This case details the management of a newly diagnosed HIV-in-
fected patient presenting with severe PCP requiring ITU admis-
sion for mechanical ventilation and ECMO. Treatment using 
second-line medications active against Pneumocystis spp. along 
with rescue therapy with caspofungin was used to good effect.
pneumocystis pneumonia
P. jirovecii disease came to prominence in the last few decades 
following the surge of HIV cases in the 1980s/1990s.18 19 In 
1981, it was first described as an opportunistic infection seen 
in homosexual men in America before the HIV virus had been 
identified.18 Prior to the introduction of ART and use of prophy-
lactic medication, about 60% of people infected with HIV in 
USA, Europe and Australia were diagnosed with P. jirovecii.1 In 
addition, cases are seen in non-HIV immunosuppressed groups 
such as those receiving antitumour therapy and post-transplan-
tation immunosuppression.20
P. jirovecii phylogenetic analysis places it within the fungal 
kingdom.1 19 21 Notably, they are unable to grow in fungal culture 
media19 and contain cholesterol instead of ergosterol in their cell 
wall.5 The risk of developing disease is significantly associated 
with CD4+ counts of <200 cells/µL and prophylaxis is given to 
those with counts below this figure.19
Clinical presentation usually involves dyspnoea on exertion, 
a dry and non-productive cough, and fever. In HIV-positive 
patients a significant degree of immunosuppression is required, 
and in those newly diagnosed with HIV these respiratory symp-
toms will likely have developed in the context of deteriorating 
health for a number of months.1 19 Radiographic signs on chest 
X-ray have a classical bilateral and diffuse interstitial infiltrates, 
as seen in figure 1 of our case. Immunofluorescence antibody 
stain has improved disease detection rate over traditional 
Gomori methenamine silver or Giemsa stains.2 20 PCR tech-
niques are used, but these may not indicate a diseased state as P. 
jirovecii colonisation is increasingly found.2 20 22
management of pcp—the role of echinocandins
First-line treatment is with cotrimoxazole (trimethoprim-sulfa-
methoxazole),2 19 with second-line treatment consisting of either 
clindamycin with primaquine, atovaquone (in mild or moderate 
cases) or in severe cases of treatment-resistant PCP, intravenous 
pentamidine which is rarely used due to its significant adverse 
effect profile.2 19 The antifungal class of echinocandins, in 
particular caspofungin, has shown activity against Pneumocystis 
spp. in vitro23 and in vivo24 mouse models. This is quite likely 
through the echinocandin’s action on (1,3)-β-D-glucan synthesis 
expressed by Pneumocystis spp. cell walls.5
There have been a few observational reports published 
looking at the effect of echinocandin therapy on PCP outcomes, 
but these have focused on infection related to non-HIV immu-
nosuppression and have conflicting conclusions.25–28 There have 
been no well-constructed observational or interventional studies 
quantifying the association between caspofungin and treatment 
outcomes in either HIV-positive or negative cohorts.
pcp and ventilation
Severe acute respiratory failure remains a common presenta-
tion among patients with PCP.29 30 Moderate-to-severe PCPs 
requiring mechanical ventilatory support have a very poor 
prognosis, with a case fatality rate between 50% and 70%.6 
Strategies in mechanically ventilated patients targeting 
tidal volumes of 4–6 mL/kg of ideal body weight to main-
tain plateau pressures less than 30 cmH2O, as per current 
evidence for managing patients with ARDS,16 have been 
shown to reduce mortality in this population (adjusted OR 
0.76 per 1 mL/kg decrease, CI 0.58 to 0.99).7 Non-invasive 
ventilation methods offer an alternative ventilation strategy 
or may avoid the need for mechanical ventilation, but larger 
and more rigorous studies are required to assess survival 
benefits.31
PCP can be frequently complicated by cystic forma-
tions and pneumotoceles which place patients at higher 
risks of developing spontaneous or iatrogenic pneumo-
thoraces and pneumomediastinal disease.32 Mortality in 
patients requiring mechanical ventilation has previously 
been reported between 60% and 80%.33 Hence, avoidance 
of positive pressure ventilation (invasive or non-invasive) 
through use of an extracorporeal circuit for gas exchange 
could theoretically reduce the risk of barotrauma and pneu-
mothorax development.29
ecmo in pcp
The main goal in the management of ARDS is to treat the 
precipitating cause and support the respiratory system with 
Figure 8 Postchest drain insertion high-resolution CT (lung bases).
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novel treatment (new drug/intervention; established drug/procedure in new situation)
lung-protective ventilation strategies.16 ECMO is a cardio-
pulmonary strategy that can be initiated as a rescue option 
in cases of ARDS where there is a severe but potentially 
reversible respiratory failure despite optimal lung-venti-
lation strategies. There are two main methods: veno-ve-
nous ECMO (VV-ECMO), which employs a central vein 
as a cannulation site for subsequent oxygenation and CO2 
removal; and venoarterial ECMO (VA-ECMO), which 
involves the cannulation of a central artery and provides 
haemodynamic as well as respiratory support.8 The former 
is the modality that has been most recently evaluated for use 
as supportive therapy in severe acute respiratory failure.10 
The Extracorporeal Life Support Organization (ELSO) 
guidelines recommend considering extracorporeal support 
based on risk of mortality (as defined by oxygen require-
ments and/or clinical scoring).9 34 35 ECMO can be used in 
these settings as rescue therapy in those who cannot maintain 
adequate gas transfer despite positive-pressure ventilation, 
or alternatively, to support lung-protective ventilation strat-
egies in those would not tolerate the ensuing hypercapnia.8
The use of ECMO as rescue treatment of ARDS caused 
by infectious precipitants is becoming more common, but 
its use is still unclear. The CESAR (Conventional Ventila-
tion or ECMO for Severe Adult Respiratory Failure) trial 
found improved mortality outcomes in patients with severe 
ARDS retrieved and cared for in a specialist ECMO centre, 
with two-thirds in each study arm being composed of infec-
tious pneumonia-related ARDS.9 The CESAR trial did not 
directly compare the use of ECMO against conventional 
ventilation strategies, but suggested the survival benefit 
was likely due to cases being cared for through a specialist 
severe acute respiratory failure pathway. In observational 
cohorts and meta-analysis looking at the use of ECMO in 
H1N1 influenza-related ARDS, in-hospital mortality rates 
consistently remained high.10 11 Furthermore, with specific 
reference to patients presenting with immunosuppression, 
ELSO guidelines have listed pharmacological immunosup-
pression (neutrophil <400/mm3) as a relative contraindi-
cation to ECMO therapy. This may lead to avoidance of 
initiating ECMO treatment in patients who may otherwise 
benefit from this.
literature review
To date, there are only a few case reports in the literature looking 
at the use of ECMO in ARDS associated with HIV-related PCP. 
We collate a comparative table of all published HIV-related cases 
of PCP that were managed with ECMO in table 1.12 13 15 36–40
As with the case described here, most reported cases 
of PCP managed with ECMO were managed using the 
VV modality. Our case presented with a profoundly raised 
HIV viral load count, likely correlating with extended 
length of untreated infection and an extremely low 
CD4 count, classifying her as a ‘late presenter’. Despite 
a prolonged period on ECMO compared with the other 
cases our patient survived hospital discharge, and this 
likely reflects factors involving her premorbid psycho-
logical profile. Three of the other published cases12 36 40 
reported the use of echinocandin therapy; with De Rosa 
et al reporting the use of caspofungin as rescue therapy as 
in our case, Gutermann et al describing the use of caspo-
fungin in the treatment of comorbid invasive Aspergillus 
spp. and Horikita et al reporting the use of micafungin as 
an apparent rescue therapy.
American41 and British42 guidance on the management of 
opportunistic infections in patients with HIV recommends 
that the optimal timing of ART initiation in those with PCP 
should be early, following the diagnosis. A randomised 
controlled trial comparing early initiation (within 14 days) 
with deferred treatment (given after treatment completion 
for any opportunistic infection present; approximately 6 
weeks) showed reduced time to AIDS progression or death 
(HR 0.53; 95% CI 0.30 to 0.92).43 The development of an 
immune reconstitution inflammatory syndrome (IRIS) is 
an important factor contributing to the timing of initiating 
ART therapy. Although cases of IRIS post-ART initiation in 
PCP have been detailed,44 the reported incidence is low. In 
the case presented here, given the level of immunosuppres-
sion and the severity of the PCP, it was safest to establish 
treatment for 2 weeks and use this period to monitor for the 
emergence of any other opportunistic infections, including 
those more commonly associated with an IRIS, before initi-
ating ART. This patient had not deteriorated significantly 
after commencing ART and this is consistent with her CD4 
count, which had very slowly increased. In other patients, 
steep rises in CD4 counts can occur shortly after initiating 
ART, and it is these patients who often deteriorate clinically.
The success of ECMO therapy in our case allowed for 
extubation from mechanical ventilation while on ECMO. 
The use of ECMO in awake and self-ventilating patients 
with respiratory failure is an increasingly more commonly 
seen treatment strategy (‘awake’ ECMO).45 46 In the case of 
our patient with PCP, the benefits of awake ECMO included 
the liberation from invasive mechanical ventilation and 
subsequent protection from ventilation-associated compli-
cations (reduced risk of barotrauma and reduced risk of 
acquired ITU-associated deconditioning) and therapy-orien-
tated factors (reduction in delirium and improved rehabili-
tation potential).45 To our knowledge, the patient presented 
in this case was the first PCP case to be managed with an 
‘awake’ ECMO strategy. However, despite the physiological 
benefit seen in ECMO, the patient presented in this case 
ultimately developed negative psychological sequelae that 
likely impeded her overall clinical improvement. It must be 
learning points
 ► Extracorporeal membrane oxygenation (ECMO) represents 
a viable therapeutic strategy for patients presenting with 
pneumocystis pneumonia (PCP)-associated acute respiratory 
distress syndrome. ECMO allows facilitation of ultra-lung 
protective ventilation strategies and awake ECMO may 
provide further ventilation, rehabilitation and psychological 
benefits. The selection of patients for veno-venous ECMO 
remains difficult, particularly in immunocompromised 
patients, and further work should be done to investigate the 
benefit of ECMO therapy in this patient group.
 ► Caspofungin therapy may provide clinical benefits in the 
management of patients with PCP, particularly in cases where 
first-line therapy is not tolerated. Randomised controlled 
trials assessing their effectiveness are required.
 ► ECMO rescue therapy can be a very traumatic experience for 
patients both physiologically and psychologically. Considering 
premorbid psychological factors and long-term quality-of-
life outcomes is important for clinicians when assessing 
candidates for ECMO.
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novel treatment (new drug/intervention; established drug/procedure in new situation)
stated that the long-term negative effects that ECMO may 
have on clinical outcomes have been documented previ-
ously. Indicators of psychological morbidity including func-
tional quality-of-life scores47 48 and return to work49 were 
all reduced in patients who had undergone ECMO.
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